Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 124 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epilepsy, Drug Resistant Clear all
Recruiting Not applicable Interventional

Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs

NCT06545643
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Dreem headband
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Not applicable Interventional

Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet

NCT03790436
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Seizures, Seizure Disorder, Ketogenic Dieting, Ketosis
Interventions
Betaquik
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 15, 2026, 5:05 AM EST
Completed Not applicable Interventional

Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy

NCT02950636
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Yoga
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 1 Interventional

Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy

NCT02286986
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol
Drug
Lead sponsor
University of Utah
Other
Eligibility
2 Years to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Nov 15, 2026, 5:05 AM EST
Recruiting Not applicable Interventional

Characterization and Analysis of Evoked Cortical Responses in Participants With Medication-intractable Epilepsy

NCT07014592
View directory record Official record
Conditions
Intractable Epilepsy
Interventions
stimulating probes and electrodes
Device
Lead sponsor
University of Michigan
Other
Eligibility
22 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Active, not recruiting Not applicable Interventional

Goals for Epilepsy Clinic Visits Trial

NCT05928598
View directory record Official record
Conditions
Drug Resistant Epilepsy
Interventions
Survey questionnaires, Epilepsy Visit Planner, Questionnaires for Providers
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Completed Not applicable Interventional Results available

Electrophysiologic Studies of Cognition in Epilepsy Patients

NCT05769634
View directory record Official record
Conditions
Drug-resistant Epilepsy
Interventions
Stereoelectroencephalography
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Not applicable Interventional Results available

Feasibility Study on LITT for Medical Refractory Epilepsy

NCT02820740
View directory record Official record
Conditions
Epilepsy
Interventions
NeuroBlate System
Device
Lead sponsor
Monteris Medical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Nov 15, 2026, 5:05 AM EST
No Longer Available No phase listed Expanded access

Stiripentol in Dravet Syndrome

NCT01533506
View directory record Official record
Conditions
Dravet Syndrome
Interventions
stiripentol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
11 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Phase 2 Interventional Results available

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

NCT01545518
View directory record Official record
Conditions
Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System, Limbic Encephalitis
Interventions
IVIG
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 2 Interventional

The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy

NCT05019885
View directory record Official record
Conditions
Drug Resistant Epilepsy, Medically Refractory Epilepsy, Refractory Epilepsy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Madeline Fields
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NCT07222878
View directory record Official record
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Phase 3 Interventional Results available

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

NCT02519439
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Nov 15, 2026, 5:05 AM EST
Not listed Phase 1Phase 2 Interventional

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

NCT04219995
View directory record Official record
Conditions
Intractable Epilepsy, Convulsive Seizures
Interventions
methylprednisolone sodium succinate, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Nov 15, 2026, 5:05 AM EST
Recruiting Not applicable Interventional

Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation

NCT02846272
View directory record Official record
Conditions
Intractable Epilepsy
Interventions
Observation
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 15, 2026, 5:05 AM EST
Approved For Marketing No phase listed Expanded access

Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

NCT02660255
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
1 Year to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 1 Interventional

ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)

NCT03646240
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
ABI-009
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
3 Years to 26 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Nov 15, 2026, 5:05 AM EST
Recruiting Not applicable Interventional

Neural Mechanisms of Spatial Representations Beyond the Self

NCT05406349
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Self-navigation task, Observation task
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Recruiting No phase listed Observational

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

NCT07546253
View directory record Official record
Conditions
Drug Resistant Epilepsy, Refractory Epilepsy
Interventions
Participants are not assigned an intervention as part of the study.
Other
Lead sponsor
NeuroOne Medical Technologies Corporation
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Miami, Florida • Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 15, 2026, 5:05 AM EST
Completed Phase 1 Interventional

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

NCT06387186
View directory record Official record
Conditions
Refractory Epilepsy, Drug Resistant Epilepsy
Interventions
Leucine-Enriched Essential Amino Acid powder
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
2 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 15, 2026, 5:05 AM EST
Enrolling by invitation Not applicable Interventional

TMS - Intracranial Electrodes

NCT03702127
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Aaron Boes
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Nov 15, 2026, 5:05 AM EST